FATE
Fate Therapeutics, Inc.
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Best Biotech Stocks 2026 →
Fate Therapeutics (FATE) Stock: Buy, Sell, or Hold?
$1.77
-0.17 (-8.76%)
▼
5d:
-13.24%
30d:
-16.9%
90d:
-34.93%
QUANTITATIVE VERDICT
WAIT
LOW Confidence (77%)
Quality Score
41/100
Position
OVERSOLD
30-Day Fair Range
$1.90 – $2.21
Position: OVERSOLD
Forward P/E & Valuation
-1.8x
Next 12M consensus est.
Wall Street Target
$5.72
+223.3% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$1.70 / $2.23
Trend: Downtrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
⏸️ WAIT FOR STABILIZATION: FATE is down 13.2% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
Get Alerted When FATE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
In-depth Analysis How we analyze
Valuation Analysis: FATE is currently trading at $1.77, which is considered oversold relative to its 30-day fair value range of $1.90 to $2.21.
Technical Outlook: Technically, FATE is in a downtrend. Immediate support is located at $1.70, while resistance sits at $2.23. Short-term momentum is weak, with the stock down 8.8% recently.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $5.72 (+223.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, FATE is in a downtrend. Immediate support is located at $1.70, while resistance sits at $2.23. Short-term momentum is weak, with the stock down 8.8% recently.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $5.72 (+223.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.90 -
$2.21
Company Quality Score
41/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
Trading Range & Key Levels
30-Day Trading Range
$1.90 -
$2.21
Current vs Trading Range
OVERSOLD
Support Level
$1.70
Resistance Level
$2.23
Current Trend
Downtrend
Technical data as of
Nov 10, 2026
Quantitative Signal Breakdown
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-8.8%)
- BULLISH: Trading 223.3% below Wall St target ($5.72)
- WARNING: Composite score 41/100 in the bottom quintile — this cohort historically lags the market
Fundamental Context
Forward P/E (Next Year Est.)
-1.82
Wall Street Target
$5.72
(+223.3%)
Revenue Growth (YoY)
9.2%
Share FATE Analysis
Share this live FATE analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (FATE)
Bearish
4 Retail Mentions
Reddit / WSB Comments
1
Bearish
StockTwits Volume
3 msgs
24h retail stream
Last Tracked
Nov 10, 2026
Daily AI digest
AI Retail Discussion Summary:
Investors on StockTwits express bullish sentiment towards $FATE following the announcement of 100.0% complete or primary efficacy renal response in lupus nephritis patients treated with FT819 and bendamustine conditioning at Month 6.
Key Retail Themes:
FT819's efficacy in treating lupus nephritis
The convenience of outpatient treatment
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 10, 2026 9:28 PM ET
Data refreshes hourly during market hours. Next update: 10:28 PM
Data refreshes hourly during market hours. Next update: 10:28 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is FATE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ARGX
argenx NV ADR |
STRONG BUY
23 analysts |
$1147 | 47 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
24 analysts |
$145 | 31 SELL |
|
BNTX
BioNTech SE |
BUY
21 analysts |
$114 | 63 BUY |
|
IRD
Opus Genetics, Inc. |
STRONG BUY
18 analysts |
$13 | 43 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 39 SELL |
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive FATE Research Pages
